A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Фаза 3 Завершено NCT03524092

Заболевание	Ulcerative Colitis
Фаза	Фаза 3
Спонсор	Eli Lilly and Company
Статус	Завершено
Участники	1,328 участн.
Вмешательство	Mirikizumab SC, Mirikizumab IV, Placebo SC
Дата начала	19.10.2018
Дата завершения	3.11.2021
Публикация результатов	25.11.2022

Кратко

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

Week 40 · percentage of participants

Maintenance Period: Miri IR - PBO SC	25.1 percentage of participants
Maintenance Period: Miri IR - 200 mg Miri SC	49.9 percentage of participants

p-value	<0.001
Risk Difference (RD)	23.2 (95% CI 15.2–31.2)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский